<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02916459</url>
  </required_header>
  <id_info>
    <org_study_id>19G 1.1-2016</org_study_id>
    <nct_id>NCT02916459</nct_id>
  </id_info>
  <brief_title>EBUS-TBNA vs Flex 19G EBUS-TBNA</brief_title>
  <official_title>Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Versus Flexible 19G Endobronchial Ultrasound Transbronchial Needle (Flex 19G EBUS-TBNA) in the Assessment of Mediastinal and Hilar Lymph-adenopathy: a Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Olympus Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <brief_summary>
    <textblock>
      This is a prospective randomised diagnostic clinical study to determine whether the use of a
      new flexible sampling needle can improve the yield of endobronchial ultrasound guided
      transbronchial needle aspiration (EBUS-TBNA). Patients undergoing EBUS-TBNA for clinical
      reasons as deemed necessary by the managing physician or multidisciplinary team will be
      randomised to undergo either EBUS-TBNA or Flex 19G EBUS-TBNA. The procedure will be performed
      under local anaesthesia using conscious sedation or general anaesthesia according to usual
      practice at the trial centre. Specimens will be placed in saline and formalin and forwarded
      to the pathology laboratory. The specimens will be spun down to create a cell pellet which
      will undergo cytological and histological examination as per usual protocol at the trial
      centre.The pathologist, who will be blinded as to which technique was used to obtain the
      sample, will grade the quality, quantity, and cellularity of the specimens.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in quality of diagnostic tissue obtained between the two study arms following 4 separate needle punctures per lymph node</measure>
    <time_frame>1 week</time_frame>
    <description>Both specimens (cell pellet and tissue fragments) will be assessed by means of a semiquantitative assessment of material (normal lymph node or lesional tissue) present using the formal scoring system described by Mair</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference between the two study arms in the percentage of lymph nodes sampled where enough tissue is obtained for complete immunohistochemical and genetic mutation analysis</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in complication rates between the two study arms</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between the two study arms in yield (quantity of diagnostic material) in patients ultimately diagnosed with sarcoidosis</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between the two study arms in yield (quantity of diagnostic material) in patients ultimately diagnosed with lymphoma</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in sensitivity for detecting sarcoidosis between the two study arms</measure>
    <time_frame>1 week</time_frame>
    <description>Sensitivity = True Positives/(True Positives + False Negatives)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in sensitivity for detecting lymphoma between the two study arms</measure>
    <time_frame>1 week</time_frame>
    <description>Sensitivity = True Positives/(True Positives + False Negatives)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Lymphadenopathy</condition>
  <condition>Lung Cancer</condition>
  <condition>Sarcoidosis</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>EBUS-TBNA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flex 19G EBUS-TBNA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>21G EBUS-TBNA needle</intervention_name>
    <arm_group_label>EBUS-TBNA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flexible 19G EBUS-TBNA needle</intervention_name>
    <arm_group_label>Flex 19G EBUS-TBNA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Scheduled for EBUS-TBNA as part of clinical care

          2. Lymph nodes larger than 10mm in diameter

          3. Age &gt; 18 years

          4. written informed consent

        Exclusion Criteria:

          1. Contraindication to needle biopsy (e.g. coagulopathy, anticoagulation,
             thrombocytopenia)

          2. Inability to obtain informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Felix Herth, Prof. Dr.</last_name>
    <phone>+49-(0)6221-396-1201</phone>
    <email>herth@uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pneumology and Critical Care medicine</name>
      <address>
        <city>Heidelberg</city>
        <state>BW</state>
        <zip>69190</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix JF Herth, MD, PhD</last_name>
      <phone>+49 6221 396</phone>
      <phone_ext>1200</phone_ext>
      <email>felix.herth@thoraxklinik-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Felix JF Herth, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralf Eberhardt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Felix JF Herth</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Lymphadenopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

